criteria. Among them, 643 (29.66%) patients had received cranial irradiation. Median follow-up time was 6.41 years (range, 6 months to 14.21 years). Median age at the time of diagnosis of all SPMs was 66.66 years (range, 21.5-91.25 years). A total of 35 (1.6%) patients developed 39 SPMs, an observed/expected (O/E) ratio of 1.43 (CI, 1.01-1.95; P 5 .04), and an AER of 18.63 per 10 000 population (see Table 1 ). Median age of the patients who developed SPM was 57 years (range, 18-87 years). There was a significantly higher risk of lung and bronchial tumors and hematologic malignancies (6 acute myeloid leukemia [AML] and 2 non-Hodgkin lymphoma cases). AML was increased (O/E 5 36.25; CI, 11.77-84.6; P , .001) within the first 5 years after ALL diagnosis. Lung and bronchial malignancies were significantly increased (O/E 5 5.52; CI 2.03-12.02; P 5 .002) after 5 years of latency.
Younger patients (age 18-59 years) had increased risk of AML (cases, 5; O/E 5 43.82; 95% CI, 14.23-102.27; P , .001; AER, 8.7 per 10 000 population) and cancer of lung and bronchus (cases, 5; O/E 5 4.04; 95% CI, 1.31-9.42; P 5 .02; AER, 6.68 per 10 000 population). Older patients ($60 years) were at higher risk of female breast cancer after 5 years of diagnosis of ALL (cases, 3; O/E 5 9.31; 95% CI, 1.92-27.20; P , .01; AER, 179.16 per 10 000 population).
Because of earlier detection of malignancies and improvement in the treatment, the number of cancer survivors is increasing and is expected to reach 18 million by 2022. 6 The cancer survivors are at risk of several long-term complications including secondary malignancies. 7, 8 A retrospective study showed increase in cumulative incidence of SPMs over 30 years after treatment of childhood ALL. 9 The majority of late-occurring SPMs were low-grade tumors. In a cohort of To the editor:
Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma
Common inherited genetic variants associated with disease risk may uncover important biological mechanisms behind neoplastic development. Here, we report a novel susceptibility locus associated with multiple myeloma (MM) risk and an additional promising locus, and we replicate 6 previously published associations. Germ line DNA was isolated from leukapheresis products obtained from a test set of 972 newly diagnosed patients of European ancestry with MM and from a validation set of 252 more recent patients treated at the Myeloma Institute for Research and Therapy. In the test set, genotyping was performed using Illumina HumanOmni1-Quad BeadChips, and genotypes have been submitted to the database of Genotypes and Phenotypes (accession no. phs000545.v1.p1). Control data for our study were downloaded from the database of Genotypes and Phenotypes and consisted of 1064 unrelated cancer-free patients of European ancestry recruited in the south-central United States for the High Density Single Nucleotide Polymorphism (SNP) Association Analysis of Melanoma (accession no. phs000187.v1.p1). 1 We excluded SNPs with greater than 2% missingness or with minor allele frequency less than 1%, as well as SNPs that violated Hardy-Weinberg equilibrium (P , .001) among control patients. We removed 2 SNPs strongly suspected of genotyping error For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
